A Phase 2 interventional study of JNJ-64565111 Dose Level 1 and JNJ-64565111 Dose Level 2 in Obesity and Diabetes Mellitus, Type 2, sponsored by Janssen Research & Development, LLC. Completed at 27 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-01-07.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Obesity by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Obesity · Johnson & Johnson.
Among the 35 studies in Obesity by Johnson & Johnson, this one is the 14th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 10 in phase 2, and was the 33rd registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →None of the 35 studies in Obesity by Johnson & Johnson is open now. The open studies under Obesity, anywhere →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 9 · Phase 4 1
First in 1998; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 113 across the 31 interventional studies, 65 across the 4 observational. Of the 35 that completed or were terminated, 13 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Obesity by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from baseline and safety and tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
Drug: JNJ-64565111 Dose Level 1
Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
Drug: JNJ-64565111 Dose Level 2
Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
Drug: JNJ-64565111 Dose Level 3
Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.
Drug: Placebo
Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.
Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.
Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.
Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
Percent Change From Baseline in Body Weight at Week 12
Percent change from baseline in body weight in kilograms (kg) at Week 12 was reported.
Time frame: Baseline, Week 12
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. An TEAE is defined as an AE with an onset after the initiation study medication and before the last study medication date of the double-blind (12-Week) treatment phase plus 35 Days.
Time frame: Up to 16 Weeks
Change From Baseline in Body Weight at Week 12
Change from baseline in body weight at Week 12 was reported.
Time frame: Baseline, Week 12
Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 12
Number of participants with \>= 5 % weight loss at Week 12 was reported.
Time frame: Week 12
| Milestone | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg |
|---|---|---|---|---|
| Started | 50 | 48 | 49 | 49 |
| Treated | 49 | 48 | 49 | 49 |
| Completed | 48 | 42 | 41 | 44 |
| Not completed | 2 | 6 | 8 | 5 |
| Withdrew: Site terminated by sponsor | 1 | 4 | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 3 | 1 |
Percent change from baseline in body weight in kilograms (kg) at Week 12 was reported.
| Percent Change | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 12 | -0.70 ± 0.50 | -5.25 ± 0.57 | -6.55 ± 0.56 | -7.92 ± 0.55 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. An TEAE is defined as an AE with an onset after the initiation study medication and before the last study medication date of the double-blind (12-Week) treatment phase plus 35 Days.
| Participants | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 28 | 30 | 39 | 36 |
Change from baseline in body weight at Week 12 was reported.
| kg | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg |
|---|---|---|---|---|
| Change From Baseline in Body Weight at Week 12 | -0.90 ± 0.577 | -5.92 ± 0.653 | -7.34 ± 0.648 | -9.04 ± 0.635 |
Number of participants with \>= 5 % weight loss at Week 12 was reported.
| Participants | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg |
|---|---|---|---|---|
| Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Weight Loss at Week 12 | 1 | 20 | 20 | 30 |
Collected over Up to 16 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/49 (0%) | 1/49 (2%) | 18/49 (36.7%) |
| JNJ-64565111 5.0 mg | 0/48 (0%) | 2/48 (4.2%) | 25/48 (52.1%) |
| JNJ-64565111 7.4 mg | 0/49 (0%) | 1/49 (2%) | 33/49 (67.3%) |
| JNJ-64565111 10.0 mg | 0/49 (0%) | 3/49 (6.1%) | 30/49 (61.2%) |
| Event | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg |
|---|---|---|---|---|
| ObesityMetabolism and nutrition disorders | 0/49 | 1/48 | 0/49 | 0/49 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/49 | 1/48 | 0/49 | 0/49 |
| BradycardiaCardiac disorders | 0/49 | 0/48 | 1/49 | 0/49 |
| Gastroenteritis ViralInfections and infestations | 0/49 | 0/48 | 0/49 | 1/49 |
| Incarcerated Incisional HerniaInjury, poisoning and procedural complications | 0/49 | 0/48 | 0/49 | 1/49 |
| HyponatraemiaMetabolism and nutrition disorders | 0/49 | 0/48 | 0/49 | 1/49 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 1/49 | 0/48 | 0/49 | 0/49 |
| Event | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/49 | 13/48 | 17/49 | 21/49 |
| VomitingGastrointestinal disorders | 0/49 | 8/48 | 12/49 | 17/49 |
| ConstipationGastrointestinal disorders | 2/49 | 4/48 | 9/49 | 4/49 |
| Decreased AppetiteMetabolism and nutrition disorders | 2/49 | 5/48 | 7/49 | 7/49 |
| DiarrhoeaGastrointestinal disorders | 2/49 | 3/48 | 2/49 | 6/49 |
| Lipase IncreasedInvestigations | 2/49 | 2/48 | 3/49 | 6/49 |
| Amylase IncreasedInvestigations | 2/49 | 2/48 | 5/49 | 3/49 |
| Abdominal DistensionGastrointestinal disorders | 3/49 | 2/48 | 0/49 | 4/49 |
| FatigueGeneral disorders | 1/49 | 1/48 | 4/49 | 1/49 |
| Pancreatic Enzymes IncreasedInvestigations | 0/49 | 1/48 | 4/49 | 0/49 |
Safety analysis set included all randomized participants who had received at least one dose of study drug.
| Age, Continuous(years) | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg | Total |
|---|---|---|---|---|---|
| Mean | 57.4 ± 9.09 | 55.1 ± 9.56 | 57.8 ± 8.97 | 56.2 ± 8.57 | 56.6 ± 9.04 |
| Sex: Female, Male(Participants) | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg | Total |
|---|---|---|---|---|---|
| Female | 30 | 32 | 28 | 28 | 118 |
| Male | 19 | 16 | 21 | 21 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 12 | 14 | 15 | 51 |
| Not Hispanic or Latino | 39 | 36 | 35 | 34 | 144 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 12 | 10 | 13 | 17 | 52 |
| White | 36 | 38 | 34 | 31 | 139 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | JNJ-64565111 5.0 mg | JNJ-64565111 7.4 mg | JNJ-64565111 10.0 mg | Total |
|---|---|---|---|---|---|
| UNITED STATES | 49 | 48 | 49 | 49 | 195 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Apr 2019, 9 months.
Results were first posted in Jan 2020, 9 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 9 months is below that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efinopegdutide
Janssen Research & Development, LLC →